Literature DB >> 32606104

Antipsychotic pitfalls: idiopathic intracranial hypertension and antipsychotic-induced weight gain.

Hirofumi Namiki1.   

Abstract

Idiopathic intracranial hypertension (IIH) is a condition associated with poor vision and headaches that can cause disability and reduced quality of life. The onset of IIH is typically associated with sudden weight gain and obesity, which may be due to first-generation or second-generation antipsychotics. This case involved the use of quetiapine in an obese, 28-year-old woman; she gained significant weight after starting the antipsychotic and later developed headaches and blurred vision. Reducing quetiapine and administering acetazolamide significantly improved her symptoms within 4 weeks. This case reminds physicians to consider IIH as a cause of headache and vision loss in patients who have gained weight after starting or increasing quetiapine. © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  drug interactions; drugs and medicines; drugs: psychiatry; neurology (drugs and medicines); unwanted effects / adverse reactions

Mesh:

Substances:

Year:  2020        PMID: 32606104      PMCID: PMC7328757          DOI: 10.1136/bcr-2020-236161

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  26 in total

1.  Recurrent idiopathic intracranial hypertension.

Authors:  Otar Taktakishvili; Vinay A Shah; Reza Shahbaz; Andrew Go Lee
Journal:  Ophthalmology       Date:  2008-01       Impact factor: 12.079

Review 2.  Update on the pathophysiology and management of idiopathic intracranial hypertension.

Authors:  Valérie Biousse; Beau B Bruce; Nancy J Newman
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-03-15       Impact factor: 10.154

3.  The search for causes of idiopathic intracranial hypertension. A preliminary case-control study.

Authors:  B Ireland; J J Corbett; R B Wallace
Journal:  Arch Neurol       Date:  1990-03

4.  Weight gain and recurrence in idiopathic intracranial hypertension: a case-control study.

Authors:  M W Ko; S C Chang; M A Ridha; J J Ney; T F Ali; D I Friedman; L J Mejico; N J Volpe; S L Galetta; L J Balcer; G T Liu
Journal:  Neurology       Date:  2011-05-03       Impact factor: 9.910

5.  Idiopathic intracranial hypertension: risk of recurrences.

Authors:  A Kesler; A Hadayer; Y Goldhammer; Y Almog; A D Korczyn
Journal:  Neurology       Date:  2004-11-09       Impact factor: 9.910

6.  Quetiapine and long-term weight change: a comprehensive data review of patients with schizophrenia.

Authors:  Martin Brecher; Ronald W Leong; Göran Stening; Lisa Osterling-Koskinen; A Martin Jones
Journal:  J Clin Psychiatry       Date:  2007-04       Impact factor: 4.384

7.  Long-term follow-up of idiopathic intracranial hypertension: the Iowa experience.

Authors:  V A Shah; R H Kardon; A G Lee; J J Corbett; M Wall
Journal:  Neurology       Date:  2008-02-19       Impact factor: 9.910

8.  Visual loss in pseudotumor cerebri. Follow-up of 57 patients from five to 41 years and a profile of 14 patients with permanent severe visual loss.

Authors:  J J Corbett; P J Savino; H S Thompson; T Kansu; N J Schatz; L S Orr; D Hopson
Journal:  Arch Neurol       Date:  1982-08

9.  Idiopathic intracranial hypertension (pseudotumor cerebri). Descriptive epidemiology in Rochester, Minn, 1976 to 1990.

Authors:  K Radhakrishnan; J E Ahlskog; S A Cross; L T Kurland; W M O'Fallon
Journal:  Arch Neurol       Date:  1993-01

10.  Symptoms and disease associations in idiopathic intracranial hypertension (pseudotumor cerebri): a case-control study.

Authors:  V Giuseffi; M Wall; P Z Siegel; P B Rojas
Journal:  Neurology       Date:  1991-02       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.